Table 2:
Multivariate Survival Analyses
| Model 1 80+ (n = 2,155) | Model 2 70–79 (n = 2,933) | |||||
|---|---|---|---|---|---|---|
| aHR | 95% CI | P | aHR | 95% CI | P | |
| Myeloma Treatment | 0.74 | 0.67–0.82 | <.0001 | 0.78 | 0.71–0.87 | <.0001 |
| White | REF | REF | ||||
| Black | 1.01 | 0.87–1.17 | 0.9349 | 0.88 | 0.77–1.01 | 0.0615 |
| Other Race | 0.89 | 0.72–1.09 | 0.2479 | 0.69 | 0.56–0.85 | 0.0006 |
| Male | REF | REF | ||||
| Female | 0.98 | 0.89–1.08 | 0.6330 | 0.93 | 0.85–1.03 | 0.1577 |
| Medicaid Enrollment | 1.05 | 0.94–1.18 | 0.4099 | 1.25 | 1.12–1.40 | <.0001 |
| Year of Diagnosis (per year) | 0.98 | 0.95–1.00 | 0.0813 | 0.96 | 0.93–0.98 | 0.0006 |
| Age (per year) | 1.05 | 1.04–1.07 | <.0001 | 1.05 | 1.03–1.06 | <.0001 |
| Poor Performance Status | 1.31 | 1.17–1.47 | <.0001 | 1.35 | 1.20–1.52 | <.0001 |
| Charlson Comorbidity Index (per unit) | 1.10 | 1.08–1.13 | <.0001 | 1.17 | 1.14–1.19 | <.0001 |
| CRAB Criteria | 1.34 | 1.07–1.67 | 0.0110 | 1.64 | 1.35–1.98 | <.0001 |